Global Rifaximin Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global Rifaximin market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Rifaximin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Rifaximin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Rifaximin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Rifaximin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Rifaximin include Texas Pharmaceuticals, STERIS PHARMA, Soigner Pharma, Salix Pharmaceuticals and Cassopeia Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Rifaximin, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Rifaximin, also provides the sales of main regions and countries. Of the upcoming market potential for Rifaximin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Rifaximin sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Rifaximin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Rifaximin sales, projected growth trends, production technology, application and end-user industry.
Rifaximin Segment by Company
Texas Pharmaceuticals
STERIS PHARMA
Soigner Pharma
Salix Pharmaceuticals
Cassopeia Pharmaceuticals
Rifaximin Segment by Type
200 mg Tablets
550 mg Tablets
Rifaximin Segment by Application
Hospital
Drug store
Rifaximin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rifaximin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rifaximin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rifaximin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Rifaximin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rifaximin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Rifaximin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Rifaximin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Rifaximin market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Rifaximin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Rifaximin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Rifaximin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Rifaximin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Rifaximin include Texas Pharmaceuticals, STERIS PHARMA, Soigner Pharma, Salix Pharmaceuticals and Cassopeia Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Rifaximin, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Rifaximin, also provides the sales of main regions and countries. Of the upcoming market potential for Rifaximin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Rifaximin sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Rifaximin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Rifaximin sales, projected growth trends, production technology, application and end-user industry.
Rifaximin Segment by Company
Texas Pharmaceuticals
STERIS PHARMA
Soigner Pharma
Salix Pharmaceuticals
Cassopeia Pharmaceuticals
Rifaximin Segment by Type
200 mg Tablets
550 mg Tablets
Rifaximin Segment by Application
Hospital
Drug store
Rifaximin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rifaximin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rifaximin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rifaximin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Rifaximin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rifaximin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Rifaximin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Rifaximin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
182 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Rifaximin Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Rifaximin Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global Rifaximin Sales Estimates and Forecasts (2020-2031)
- 1.5 Global Rifaximin Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Rifaximin Market Dynamics
- 2.1 Rifaximin Industry Trends
- 2.2 Rifaximin Industry Drivers
- 2.3 Rifaximin Industry Opportunities and Challenges
- 2.4 Rifaximin Industry Restraints
- 3 Rifaximin Market by Manufacturers
- 3.1 Global Rifaximin Revenue by Manufacturers (2020-2025)
- 3.2 Global Rifaximin Sales by Manufacturers (2020-2025)
- 3.3 Global Rifaximin Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global Rifaximin Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Rifaximin Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Rifaximin Manufacturers, Product Type & Application
- 3.7 Global Rifaximin Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Rifaximin Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Rifaximin Players Market Share by Revenue in 2024
- 3.8.3 2024 Rifaximin Tier 1, Tier 2, and Tier 3
- 4 Rifaximin Market by Type
- 4.1 Rifaximin Type Introduction
- 4.1.1 200 mg Tablets
- 4.1.2 550 mg Tablets
- 4.2 Global Rifaximin Sales by Type
- 4.2.1 Global Rifaximin Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Rifaximin Sales by Type (2020-2031)
- 4.2.3 Global Rifaximin Sales Market Share by Type (2020-2031)
- 4.3 Global Rifaximin Revenue by Type
- 4.3.1 Global Rifaximin Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Rifaximin Revenue by Type (2020-2031)
- 4.3.3 Global Rifaximin Revenue Market Share by Type (2020-2031)
- 5 Rifaximin Market by Application
- 5.1 Rifaximin Application Introduction
- 5.1.1 Hospital
- 5.1.2 Drug store
- 5.2 Global Rifaximin Sales by Application
- 5.2.1 Global Rifaximin Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Rifaximin Sales by Application (2020-2031)
- 5.2.3 Global Rifaximin Sales Market Share by Application (2020-2031)
- 5.3 Global Rifaximin Revenue by Application
- 5.3.1 Global Rifaximin Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Rifaximin Revenue by Application (2020-2031)
- 5.3.3 Global Rifaximin Revenue Market Share by Application (2020-2031)
- 6 Global Rifaximin Sales by Region
- 6.1 Global Rifaximin Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Rifaximin Sales by Region (2020-2031)
- 6.2.1 Global Rifaximin Sales by Region (2020-2025)
- 6.2.2 Global Rifaximin Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Rifaximin Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America Rifaximin Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Rifaximin Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe Rifaximin Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Rifaximin Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific Rifaximin Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Rifaximin Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa Rifaximin Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global Rifaximin Revenue by Region
- 7.1 Global Rifaximin Revenue by Region
- 7.1.1 Global Rifaximin Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global Rifaximin Revenue by Region (2020-2025)
- 7.1.3 Global Rifaximin Revenue by Region (2026-2031)
- 7.1.4 Global Rifaximin Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America Rifaximin Revenue (2020-2031)
- 7.2.2 North America Rifaximin Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe Rifaximin Revenue (2020-2031)
- 7.3.2 Europe Rifaximin Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Rifaximin Revenue (2020-2031)
- 7.4.2 Asia-Pacific Rifaximin Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Rifaximin Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa Rifaximin Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Texas Pharmaceuticals
- 8.1.1 Texas Pharmaceuticals Comapny Information
- 8.1.2 Texas Pharmaceuticals Business Overview
- 8.1.3 Texas Pharmaceuticals Rifaximin Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Texas Pharmaceuticals Rifaximin Product Portfolio
- 8.1.5 Texas Pharmaceuticals Recent Developments
- 8.2 STERIS PHARMA
- 8.2.1 STERIS PHARMA Comapny Information
- 8.2.2 STERIS PHARMA Business Overview
- 8.2.3 STERIS PHARMA Rifaximin Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 STERIS PHARMA Rifaximin Product Portfolio
- 8.2.5 STERIS PHARMA Recent Developments
- 8.3 Soigner Pharma
- 8.3.1 Soigner Pharma Comapny Information
- 8.3.2 Soigner Pharma Business Overview
- 8.3.3 Soigner Pharma Rifaximin Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Soigner Pharma Rifaximin Product Portfolio
- 8.3.5 Soigner Pharma Recent Developments
- 8.4 Salix Pharmaceuticals
- 8.4.1 Salix Pharmaceuticals Comapny Information
- 8.4.2 Salix Pharmaceuticals Business Overview
- 8.4.3 Salix Pharmaceuticals Rifaximin Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Salix Pharmaceuticals Rifaximin Product Portfolio
- 8.4.5 Salix Pharmaceuticals Recent Developments
- 8.5 Cassopeia Pharmaceuticals
- 8.5.1 Cassopeia Pharmaceuticals Comapny Information
- 8.5.2 Cassopeia Pharmaceuticals Business Overview
- 8.5.3 Cassopeia Pharmaceuticals Rifaximin Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 Cassopeia Pharmaceuticals Rifaximin Product Portfolio
- 8.5.5 Cassopeia Pharmaceuticals Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Rifaximin Value Chain Analysis
- 9.1.1 Rifaximin Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Rifaximin Production Mode & Process
- 9.2 Rifaximin Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Rifaximin Distributors
- 9.2.3 Rifaximin Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

